Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTG/3TC vs BIC/FTC/TAF maintenance therapy in people living with HIV
2020-003686-18Phase 4Active
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in human immunodeficiency virus infection (HIV) comparing DTG/3TC (Dovato) maintenance therapy with BIC/FTC/TAF (Biktarvy) maintenance therapy (2 arms). Primary endpoint: Virological failure at week 48. Started Dec 2021; status: active.
02
Drugs
dolutegravir + lamivudinebictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2020-003686-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003686-18.